We're thrilled to announce the completion of a $106.6 million Series C financing to progress our lead LYTAC extracellular protein degraders into the clinic for unmet needs in #autoimmune and #inflammatory diseases. Venrock Healthcare Capital Partners led the round, with participation from new investors Janus Henderson Investors, Marshall Wace and Franklin Templeton, and existing investors Redmile Group, RTW Investments, LP, Blue Owl Capital (Blue Owl Healthcare Opportunities), Invus, Eli Lilly and Company and Alexandria Venture Investments. Read the release: https://bit.ly/44EG63u
Congrats Aetna Wun Trombley and team!
🎉🎊💪🏻
Congratulations!
Congratulations!
Best of luck!
Congratulations to Lycia and to you, Aetna!!
Awesome!
Congratulations! Very exciting news!
Lycia Therapeutics Congrats on your series C!